CAR-T cell therapy: DCGI approves NexCAR19 for blood cancer treatment - Video

Published On 2023-10-17T15:07:01+05:30 | Updated On 17 Oct 2023 3:07 PM IST

Overview

Immunoadoptive Cell Therapy Private Limited (“ImmunoACT”) has received the marketing authorization approval for the first humanized CD19-targeted Chimeric Antigen Receptor T cell (CAR-T cell) therapy product for relapsed / refractory (r/r) B-cell lymphomas and leukemia in India.

NexCAR19 is an indigenously developed CD19 targeted CAR-T cell therapy. It is the first-of-its kind, a Made-in-India product.

The multi-center Phase I/ II pivotal clinical trial, led by Dr Hasmukh Jain, was conducted with 60 patients of r/r B-cell lymphomas and leukemia. The clinical data indicates ~70% overall response rate (ORR). The safety profile in terms of cytokine release syndrome (CRS) and absence of neurotoxicity indicates a significant improvement over the other commercially approved CD19-directed CAR-T cell therapies.

For more details, check out the link given below:

Breakthrough Made-In-India CAR-T Cell Therapy NexCAR19 Gets DCGI Nod For Blood Cancer Treatment

Speakers

Isra Zaman

B.Sc Life Sciences, M.Sc Biotechnology, B.Ed

Isra Zaman is a Life Science graduate from Daulat Ram College, Delhi University, and a postgraduate in Biotechnology from Amity University. She has a flair for writing, and her roles at Medicaldialogues include that of a Sr. content writer and a medical correspondent. Her news pieces cover recent discoveries and updates from the health and medicine sector. She can be reached at editorial@medicaldialogues.in.